Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of “progression-free survival 2” as a clinical trial end-point

Podobne knjige/članki

• Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial
  od: Dimopoulos, Meletios A., et al.
  Izdano: (2013)
• Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial
  od: Dimopoulos, Meletios A., et al.
  Izdano: (2014)
• Treatment of newly diagnosed myeloma
  od: Palumbo, A, et al.
  Izdano: (2008)
• Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma
  od: Terpos, Evangelos, et al.
  Izdano: (2018)
• Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
  od: Dimopoulos, Meletios A., et al.
  Izdano: (2020)